Entero Healthcare Solutions Limited (ENTERO) climbed +5% to ₹1148.9 on the NSE today. The stock is rising intraday but remains within a consolidating downtrend, having not cleared resistance. This move comes as the trendline status shifted from a bounce from support to consolidating down. Entero Healthcare operates in the healthcare sector, specifically medical distribution, and today’s move appears to be more company-specific rather than a sector-wide momentum.

Technical setup — trendlines & DMA

Currently, Entero Healthcare’s 6M support trendline is at ₹1073.04, which is 6.60% below today’s price, while the resistance trendline is at ₹1373.78, 19.57% above. The stock is 9% below its 50-DMA of ₹1199.5, indicating a weak position relative to this moving average. Despite the 50-DMA being above the 200-DMA of ₹1127.3, suggesting a bullish trend, the stock is still below both moving averages, reflecting a recovery phase rather than an extended move. Entero Healthcare is trading in the middle third of its 52W range, which spans from ₹944.0 to ₹1390.0, implying that a significant portion of the potential move is already priced in.

Fundamentals & business context

With a PE of 41.3 and profit margins at 1.7%, Entero Healthcare’s valuation appears stretched relative to its current earnings, especially given its revenue CAGR of 26.0%. This suggests that the market may be pricing in expectations of a significant turnaround or future growth, which the company needs to deliver to justify its current valuation. Institutional ownership stands at 13.8%, indicating a moderate level of confidence from sophisticated investors. There is no NSE catalyst today that directly explains the move, so it seems to be driven by market sentiment and technical factors.

Algorithmic scorecard

Entero Healthcare’s overall algorithmic scorecard of 61 reflects a balanced but cautious view, with strengths in certain areas offset by weaknesses in others. One of the strongest signals is the revenue CAGR of 26.0%, which indicates robust top-line growth and business stability, as revenue has grown consistently every year. Another positive is the very low debt level, with a D/E ratio of 0.22, signaling excellent financial health. On the weaker side, the profit margin of 1.7% is notably low, leaving little room for error if costs rise or revenue growth slows. Additionally, the negligible dividend yield of 0% means there is little to no income generation from this stock, which could be a concern for income-focused investors.

Company outlook

Entero Healthcare’s management has outlined an ambitious plan for FY27, targeting consolidated revenue growth of 23% year-on-year, excluding new acquisitions, with an EBITDA margin of 5%. The focus will be on profitable revenue growth and operational efficiencies to drive margins. Management expects the EBITDA to operating cash flow conversion ratio to be at least 50% for FY27, ensuring sustainable growth. The tax rate is projected to be around 22% – 23%, and minority interest is expected to be 25% – 27% of PAT before minority interest. Working capital as a percentage of sales is expected to decrease directionally. The company plans to focus on organic growth for the next 6 to 8 months, without any new acquisitions, and aims to maintain a strong EBITDA to operating cash flow conversion ratio of at least 50%.

Get all details on ENTERO — P&L, peers, shareholding and more on TradeAlone.